Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz
|Bid||15.50 x 0|
|Ask||15.55 x 0|
|Day's Range||15.45 - 15.95|
|52 Week Range||12.65 - 17.10|
|PE Ratio (TTM)||-9.00|
|Earnings Date||Nov 8, 2017 - Nov 13, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||12.90|
Editor's Summary: Acer is listed on DJSI's Emerging Markets Index for the fourth consecutive year, and on the FTSE4Good Emerging Index for the second consecutive year DJSI: In addition to continuing to ...
TAIPEI, Taiwan, Sept. 5, 2017 /PRNewswire/ -- Acer (TWSE: 2353, LSE: ACID) will showcase its service-oriented and intelligent mixology robot solution, the MixBot, at the 2017 Taipei International Industrial Automation Exhibition. The Acer MixBot solution, which integrates a robotic arm and an autonomous guided vehicle (AGV), will demonstrate a complete bartending solution from order-taking, drink preparation, and table service to customers, along with a business intelligence system at the backend. The MixBot shows how Acer can fully customize its robotic solutions for a variety of usage scenarios.
Acer Therapeutics, a three-year-old Cambridge biotech developing drugs for ultra-rare diseases, said Monday that it will go public through a reverse merger with a small Texas company. Acer said it would merge with Opexa Therapeutics (OPXA), which laid off all but two of its 20 employees after its lead drug for multiple sclerosis flunked a mid-stage trial in October. In connection with the deal, Acer said it would receive a $15.7 million round of financing led by TVM Capital, a life sciences venture firm based in Germany.